January 30, 2017
3 min read

Few women with early-stage breast cancer seek second opinion

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Very few women with early-stage breast cancer pursue a second opinion when considering cancer treatments, according to survey data recently published in JAMA Oncology.

“Second opinions can facilitate treatment decision-making and should be encouraged when patients are uncertain about their options or lack confidence in the treatment decision process,” Allison W. Kurian, MD, MSc, associate professor of medicine and of health research and policy at Stanford University, and colleagues wrote. “However, little is known about how patients are referred to a medical oncologist after diagnosis, and, surprisingly, virtually nothing is known about the patterns and correlates of second opinions in community practice or the implications for quality of care.”

Researchers used two Surveillance, Epidemiology, and End Results registries in Georgia and Los Angeles County, California to identify 1,901 women (mean age, 61.6 years) who had been diagnosed with breast cancer between July 2013 and Sept. 2014. All women were between stage 0 and stage II.

One thousand seventy-one patients (56.3%) were white, 17.3% were Hispanic, 16.1% were black and 7.4% were Asian. Sixty-one percent had a high school-level education or lower. Most (62.8%) had stage I disease.

A weighted data analysis showed that 168 women (9.8%) received a second opinion, 54 (3.2%) of whom underwent chemotherapy with their second oncologist.

Satisfaction with treatment did not significantly differ between those who did and did not get a second opinion (4.3 vs. 4.4 on a 5-point scale).

The use of internet support groups (OR = 2.15; 95% CI, 1.12-4.11), a college education compared with less education (OR = 1.85; 95% CI, 1.24-2.75), intermediate 21-gene recurrence score assay results (OR = 1.85; 95% CI, 1.11-3.09) and uncertain significance on hereditary cancer genetic testing (OR = 3.24; 95% CI, 1.09-9.59) were all predictive of a patient seeking second opinion.

“Our results indicate that a patient’s preference for greater engagement is one factor contributing to second opinion use, and uncertain results of diagnostic testing are another,” the researchers wrote. “As treatment options proliferate and molecular diagnostic tests expand, physicians may face increasing pressure to enable patients’ preferences about treatment decision-making and to navigate the increasingly murky landscape of genomic testing. These tasks demand effective physician–patient communication, and developing interventions to enhance the quality of such communication is a high priority.” – by Andy Polhamus

Disclosure: The researchers report no relevant financial disclosures.